These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Risk factors for postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas based on a long-term follow-up study: proposals for follow-up strategies. Yogi T, Hijioka S, Imaoka H, Mizuno N, Hara K, Tajika M, Tanaka T, Ishihara M, Shimizu Y, Hosoda W, Yatabe Y, Niwa Y, Yoshimura K, Bhatia V, Fujita J, Yamao K. J Hepatobiliary Pancreat Sci; 2015 Oct; 22(10):757-65. PubMed ID: 26148131 [Abstract] [Full Text] [Related]
47. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Yamaguchi K, Kanemitsu S, Hatori T, Maguchi H, Shimizu Y, Tada M, Nakagohri T, Hanada K, Osanai M, Noda Y, Nakaizumi A, Furukawa T, Ban S, Nobukawa B, Kato Y, Tanaka M. Pancreas; 2011 May; 40(4):571-80. PubMed ID: 21499212 [Abstract] [Full Text] [Related]
48. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Furukawa T, Hatori T, Fujita I, Yamamoto M, Kobayashi M, Ohike N, Morohoshi T, Egawa S, Unno M, Takao S, Osako M, Yonezawa S, Mino-Kenudson M, Lauwers GY, Yamaguchi H, Ban S, Shimizu M. Gut; 2011 Apr; 60(4):509-16. PubMed ID: 21193453 [Abstract] [Full Text] [Related]
50. Clinical significance of frozen section analysis during resection of intraductal papillary mucinous neoplasm: should a positive pancreatic margin for adenoma or borderline lesion be resected additionally? Nara S, Shimada K, Sakamoto Y, Esaki M, Kosuge T, Hiraoka N. J Am Coll Surg; 2009 Nov; 209(5):614-21. PubMed ID: 19854402 [Abstract] [Full Text] [Related]
51. Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules. Sadakari Y, Ienaga J, Kobayashi K, Miyasaka Y, Takahata S, Nakamura M, Mizumoto K, Tanaka M. Pancreas; 2010 Mar; 39(2):232-6. PubMed ID: 19752768 [Abstract] [Full Text] [Related]
57. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage. Waters JA, Schnelldorfer T, Aguilar-Saavedra JR, Chen JH, Yiannoutsos CT, Lillemoe KD, Farnell MB, Sarr MG, Schmidt CM. J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488 [Abstract] [Full Text] [Related]
58. Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma. Shimada K, Sakamoto Y, Sano T, Kosuge T, Hiraoka N. Pancreas; 2006 Apr; 32(3):281-7. PubMed ID: 16628084 [Abstract] [Full Text] [Related]
59. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, Howard TJ, Zyromski NJ, Nakeeb A, DeWitt JM, Akisik FM, Sherman S, Pitt HA, Lillemoe KD. Ann Surg; 2007 Oct; 246(4):644-51; discussion 651-4. PubMed ID: 17893501 [Abstract] [Full Text] [Related]
60. Intraductal papillary-mucinous neoplasms of the gastric and intestinal types may have less malignant potential than the pancreatobiliary type. Takasu N, Kimura W, Moriya T, Hirai I, Takeshita A, Kamio Y, Nomura T. Pancreas; 2010 Jul; 39(5):604-10. PubMed ID: 20124938 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]